Corporate Overview
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized platform immunotherapy that combines partial tumor oncolysis and a multi-target biologic drug. The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immune suppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body and defend with immune memory. Our lead candidate, SV-102 for mCRPC, is in Phase 2 trials. Syncromune is headquartered in Fort Lauderdale, FL, and West Des Moines, IA, USA. For more information, please visit www.syncromune.com.
Headquarters
Fort Lauderdale, FL
Founded
2020
Therapeutic Area
Immuno-Oncology
Clinical Stage
Phase 2a
Our Mission
We aspire to develop a completely in situ immunotherapy platform technology optimized for solid tumor cancers that achieves high response rates with potentially curative efficacy
Our Values
C
Caring
Every member of the Syncromune team is inspired by the opportunities to change the lives of patients and their families and bring hope to those who have exhausted their treatment options.
U
Unique
At Syncromune we are doing things that have never been done and developing a disruptive technology that is paving the way for a whole new approach to treating metastatic solid tumor cancers.
R
Relentless
We are focused every day on our pursuit of developing a cure for metastatic solid tumor cancers. Our team works relentlessly with the goal of helping patients in need.
E
Ethical
Syncromune is committed to maintaining high standards of personal conduct, practicing honesty in all our professional relationships and endeavors. We believe in being truthful in our actions and words.
The SYNC-T combination therapy consists of 3 components: a multi-target biologic drug, partial tumor oncolysis, and a proprietary procedure
SYNCHRONIZING THE POWER OF IMMUNOTHERAPY®
SYNC-T: A Powerful Platform
SYNC-T is a solid tumor platform therapy that is completely in situ and designed to provide local treatment with systemic effects. The platform can be used to treat virtually all solid tumors. The therapy can be tailored using different combinations of the multi-target biologic drug.
Versatile
The SYNC-T Therapy platform can be broadly used to treat virtually all solid tumors
In Situ
SYNC-T is a completely in situ (within the body) therapy and does not require collection of clinical samples or any lab processing.
Low Dose
Since the therapy is performed within the tumor, the intratumorally infused biologic drug is a very low dose (compared to systemic IV administration) with a locally high concentration. Lower doses could reduce toxicities and side effects.
Customizable
The platform is able to be tailored by using a different multi-target biologic drug to achieve desired therapeutic effects.
How It Works
The SYNC-T Therapy Platform is Designed to:
- Provide a personalized in situ cancer vaccine for tumor antigen recognition
- Utilize a multi-target approach to address multiple immune suppression mechanisms simultaneously
- Employ locoregional targeting that allows for lower dose administration, high local concentrations, less systemic exposure, and reduced toxicity
- Focus on reversing immune suppression in the tumor microenvironment (TME) and tumor draining lymph nodes to create systemic anti-tumor immunity and defend with immune memory
SYNC-T Animation: How it Works
Pipeline
Our current pipeline focuses on developing the SYNC-T platform therapy for metastatic solid tumor cancers. You can learn more about SYNC-T trials HERE.
Resources
Corporate Presentation
Learn more about Syncromune's approach and SYNC-T Therapy
Meet the Team
Get to know the Executive Leadership, Board of Directors, and Scientific Advisory Board
Syncromune in the News
Review the news and media coverage of Syncromune
All Current Job Openings
Review all the positions that Syncromune currently has open
Press Releases
Syncromune is an Equal Opportunity Employer
The Company is required to provide a reasonable estimate of the salary range for this job in certain states and cities within the United States. Final determinations with respect to salary will take into account a number of factors, which may include, but not be limited to, the primary work location and the chosen candidate’s relevant skills, experience, and education.
This position generally is eligible for cash incentive compensation, equity incentive compensation, and employee benefits under the Company’s benefit plans.
